Yes, you can get ovarian cysts after menopause, but they are uncommon and need a different evaluation than before menopause. Can you get ovarian cysts after menopause? Yes, and most are simple, benign, and asymptomatic. A new complex cyst in a postmenopausal woman still needs expert transvaginal ultrasound and sometimes CA-125 testing. The key distinction is not age alone; it is cyst structure, size, symptoms, and change over time. A simple 2-cm cyst has a very low malignancy risk. A complex cyst with solid areas or ascites raises concern enough for gynecologic oncology referral.
How Ovarian Cysts Form After Menopause
After menopause, the ovary stops releasing an egg each month, so the usual functional cysts become rare. Those functional cysts include follicular cysts and corpus luteum cysts, and they account for most ovarian cysts in reproductive-age women. In postmenopausal women, functional cysts make up less than 5% of newly found adnexal cysts. The ovary also shrinks over time, from roughly 4 to 8 mL in reproductive years to about 1 to 2 mL after menopause.
Most postmenopausal cysts arise from non-ovulatory structures. The ovarian surface epithelium can fold inward and form small inclusion cysts. Remnants of the Müllerian ducts, the rete ovarii, and the fallopian tube can also produce cystic lesions. Paraovarian cysts and peritoneal inclusion cysts may look ovarian on imaging but arise beside the ovary or from the peritoneum. This is why a postmenopausal “ovarian cyst” is often not a true ovarian follicle at all.
The deeper mechanism involves repeated surface injury and repair. Ovulation causes small ruptures in the ovarian surface, and the repair process can trap epithelial cells inside the ovary. After menopause, ovulation stops, but inclusion cysts can persist, enlarge, or undergo genetic changes. Established science links many high-grade serous ovarian cancers to the fallopian tube rather than the ovary itself. The idea that persistently high gonadotropins directly drive inclusion cyst growth is plausible but not proven as the main cause.
In plain terms: postmenopausal cysts are more often structural remnants or benign growths than leftover eggs. Most simple cysts are thin-walled, fluid-filled, and unilocular. Complex cysts have thick walls, septations, solid components, or debris, and those features matter more than the word “cyst.” A 1-cm simple cyst and a 10-cm simple cyst both need context, but a 3-cm cyst with a solid nodule needs faster expert review.
Can You Get Ovarian Cysts After Menopause? Causes and Frequency
Ovarian cysts after menopause are found on ultrasound in roughly 4% to 18% of women, depending on the population and the definition used. Most are asymptomatic simple cysts. The frequency rises when imaging is done for unrelated symptoms, such as bloating, urinary frequency, or pelvic pressure. Many cysts are stable for years and never cause a problem.
The causes fall into several groups. Simple epithelial inclusion cysts are common and usually benign. Serous cystadenomas and mucinous cystadenomas are benign tumors that can grow large. Dermoid cysts are less likely to first appear after menopause, but a preexisting dermoid can persist. Endometriomas can also persist after menopause, though new endometriotic cysts are uncommon. Hydrosalpinges, paraovarian cysts, and peritoneal inclusion cysts are frequent mimics of ovarian cysts. Malignant cysts are the least common but the most important to identify.
There is a useful comparison between premenopausal and postmenopausal cysts. Before menopause, functional cysts account for about 70% of ovarian cysts. After menopause, functional cysts account for less than 5%. That shift is why a new cyst after menopause gets more careful imaging and risk assessment. It is not because every postmenopausal cyst is cancer. It is because the pretest probability of a neoplastic or malignant process is higher than in a young woman with a simple follicle.
A new cyst is not the same as a stable cyst. A simple cyst that has been unchanged for years has a very low risk of malignancy. A new complex cyst, a cyst with solid areas, or a cyst with ascites requires prompt specialist evaluation. Per the 2016 ACOG Practice Bulletin on ovarian cysts, postmenopausal cysts need systematic evaluation rather than automatic surgery. The exact follow-up depends on imaging features, CA-125 when appropriate, symptoms, and family history.
Symptoms and Red Flags of Postmenopausal Cysts
Most postmenopausal ovarian cysts cause no symptoms. When symptoms occur, they usually come from size or pressure rather than from the cyst fluid itself. A cyst larger than 5 cm is more likely to cause pelvic pressure, bladder urgency, or a feeling of fullness. A 10-cm cyst can displace bowel or bladder and cause constipation or frequent urination. These symptoms are nonspecific and overlap with many benign conditions.
Ovarian cancer can also cause vague symptoms, which is why persistent changes deserve attention. Per the American Cancer Society, about 80% of ovarian cancers are diagnosed after the disease has spread beyond the ovary. That statistic does not mean every bloating episode is cancer. It means persistent, new, or worsening symptoms in a postmenopausal woman should prompt evaluation rather than watchful waiting.
Seek prompt gynecologic review for these red flags:
- Persistent bloating or abdominal distention lasting more than 2 weeks
- Pelvic or abdominal pain that is new, severe, or worsening
- Urinary urgency or frequency without infection
- Early satiety, nausea, or unintentional weight loss
- Abnormal vaginal bleeding after menopause
- A cyst that is complex, rapidly enlarging, or accompanied by ascites
A normal CA-125 does not erase a red flag. CA-125 can be normal in early ovarian cancer and elevated in benign conditions such as fibroids, endometriosis, liver disease, and heart failure. The test is most useful when combined with ultrasound and clinical context, not as a stand-alone screening test. Symptom duration and imaging features carry real weight.
Size Thresholds and Ultrasound Risk
There is no single universal size cutoff that separates benign from malignant postmenopausal cysts. Size matters, but structure matters more. A 2-cm simple cyst and a 9-cm simple cyst can both remain in a low-risk imaging category when they are thin-walled and anechoic. A 12-cm simple cyst crosses into a higher O-RADS category because large simple cysts are harder to fully assess and have a slightly higher risk of occult malignancy.
The American College of Radiology O-RADS ultrasound system, version 2022, groups adnexal lesions by estimated malignancy risk. O-RADS 2 lesions have a risk below 1%. O-RADS 3 lesions carry a 1% to under 10% risk. O-RADS 4 lesions carry a 10% to under 50% risk. O-RADS 5 lesions carry a 50% or higher risk. These are population estimates, not individual prophecies.
| Finding | Typical size context | Estimated malignancy risk | Common next step |
|---|---|---|---|
| Simple cyst, thin wall, anechoic, no solid part | Up to 10 cm often O-RADS 2 | Under 1% | Often surveillance or no follow-up if stable and asymptomatic |
| Simple cyst larger than 10 cm | Crosses into higher category | Higher than small simple cyst | Expert ultrasound review and individualized plan |
| Cyst with thick septation or solid component | Any size, but risk rises with solid areas | 10% to under 50% in O-RADS 4 patterns | Gynecologic oncology referral is common |
| Cyst with ascites, peritoneal nodularity, or large solid mass | Any size | 50% or higher in O-RADS 5 patterns | Urgent gynecologic oncology evaluation |
| Hydrosalpinx or paraovarian cyst | Often 2 to 10 cm | Usually low, but mimics ovarian cyst | Confirm origin with expert ultrasound or MRI |
A 2-cm simple cyst and a 9-cm simple cyst can both remain in the same low-risk O-RADS 2 group when they are thin-walled and anechoic, but a 12-cm simple cyst crosses into O-RADS 3. That 10-cm line is separate from the 5-cm symptom threshold and the 1-cm detection threshold. In other words, 1 cm is a detection and follow-up question, 5 cm is often a symptom and imaging-quality question, and 10 cm is a risk-category question.
Size thresholds also depend on menopause status and CA-125. A simple 3-cm cyst in a 60-year-old woman with no symptoms is usually low concern. A 3-cm cyst with a 5-mm solid nodule is a different lesion even though the overall size is small. The solid component, not the total diameter, can drive the risk category. This is why “how big is it?” is only one of several questions.
Timeline After a Cyst Is Found
The timeline below reflects a common evaluation pathway, not a universal protocol. Guidelines differ by country and specialty, and the exact plan depends on the cyst’s imaging features, the woman’s symptoms, CA-125 results, and her cancer risk. A simple cyst may need one repeat scan, while a complex cyst may need surgery without a long observation period.
| Timeframe | Step | What it resolves |
|---|---|---|
| Day 0 | Transvaginal ultrasound with gray-scale and color Doppler | Confirms whether the cyst is simple, complex, or non-ovarian |
| Within 1 to 2 weeks | Review by a gynecologist or gynecologic oncologist | Decides whether CA-125, MRI, or referral is needed |
| 3 to 6 months | Repeat ultrasound for selected low-risk lesions | Checks for growth, new septations, or solid components |
| 6 to 12 months | Further surveillance if stable and low risk | Confirms stability before stopping follow-up |
| Any visit | Reassess symptoms and red flags | Detects clinical change that overrides imaging stability |
| Before surgery | Anesthesia review and surgical planning | Balances cancer risk against surgical risk |
| After surgery | Pathology review | Provides the definitive diagnosis |
Most simple cysts that are going to remain benign stay stable. Rapid growth, new solid areas, or ascites can change triage at any interval. There is no reliable rule that a cyst must grow by a specific number of millimeters before it becomes concerning. A change in structure is often more important than a small change in diameter. Per the 2021 ESGO/ISUOG/IOTA consensus, expert ultrasound assessment and standardized terminology improve the distinction between benign and malignant adnexal masses.
Misconceptions and Edge Cases
A common misconception is that menopause means cysts cannot form because ovulation has stopped. Ovulation-related cysts do become rare, but non-ovulatory cysts can still arise from the ovarian surface, fallopian tube, paraovarian tissues, or peritoneum. Another misconception is that every postmenopausal cyst is cancer. Most simple cysts are benign, and many complex cysts are still benign cystadenomas or dermoids. The real task is separating low-risk from high-risk lesions without overreacting to every small simple cyst.
CA-125 is another source of false reassurance. A normal CA-125 does not exclude ovarian cancer, especially early-stage disease. An elevated CA-125 does not prove cancer, because many benign conditions raise it. The marker is most useful when it is interpreted with ultrasound features, menopausal status, and the overall clinical picture. It is not a screening test for average-risk women with no symptoms.
Some edge cases change the risk calculation. A woman with a BRCA1 mutation has a 39% to 44% lifetime risk of ovarian cancer, and a BRCA2 mutation carries an 11% to 18% lifetime risk, per the National Cancer Institute. A personal history of breast cancer, especially treatment with tamoxifen, can complicate ovarian cyst interpretation. Endometriomas and dermoids can persist after menopause and may not follow the same rules as simple cysts. Hydrosalpinges can mimic complex ovarian cysts, and peritoneal inclusion cysts can look multilocular.
A further caveat is that O-RADS categories are not a diagnosis. They estimate malignancy risk across a category, not for one person. A postmenopausal woman with a stable O-RADS 2 cyst and no symptoms may need less intervention than a woman with the same cyst but a strong family history. Shared decision-making matters because surgery has real risks, including infection, blood clots, bowel injury, and loss of ovarian hormone production if both ovaries are removed.
What to Actually Do, and What Remains Uncertain
If you have a new ovarian cyst after menopause, start with a transvaginal ultrasound performed by an experienced sonographer. Ask whether the report includes an O-RADS category or a clear description of the cyst’s wall, septations, solid components, and vascularity. Bring any prior ultrasound or CT images so the radiologist can compare stability. A stable simple cyst is reassuring, while a new complex feature is not.
Ask your clinician whether CA-125 testing is appropriate for your situation. Do not use CA-125 alone to rule cancer in or out. If the cyst is complex, has solid areas, is associated with ascites, or you have a strong family history, ask for gynecologic oncology referral. If you have persistent bloating, pelvic pain, urinary changes, or abnormal bleeding, report those symptoms even if the cyst is small. The symptom pattern can change the urgency of evaluation.
For low-risk simple cysts, surveillance is often reasonable. For cysts that are growing, complex, or symptomatic, surgery may be discussed. The choice between laparoscopy and laparotomy depends on cyst size, suspicion for malignancy, and surgical history. Removing a cyst without removing the ovary may be possible in some benign cases, but suspected cancer usually requires a different surgical approach. Per the American College of Radiology O-RADS system, version 2022, standardized reporting helps clinicians match the intensity of follow-up to the actual imaging risk.
The main uncertainty is that high-quality trials are limited for postmenopausal simple cysts. Guidelines vary on whether a simple cyst up to 10 cm can be safely observed when CA-125 is normal and symptoms are absent. Some societies use 5 cm as a more conservative threshold, while others use 10 cm for simple cysts. Age, family history, BRCA status, symptoms, and imaging quality all modify the decision. There is no single number that makes a cyst safe or dangerous for every woman.
What is clear is that postmenopausal ovarian cysts are not automatically cancer. They are common enough to encounter, uncommon enough to respect, and variable enough to need individualized assessment. The most useful next step is not fear or repeated CA-125 testing. It is expert transvaginal ultrasound, a clear risk category, and a plan that matches the cyst’s structure and the woman’s overall risk.